[1-(2-fluoroethyl)-1H-pyrazol-5-yl] formamide | 144991-30-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: [1-(2-fluoroethyl)-1H-pyrazol-5-yl] formamide
• 英文别名: 1-(2-fluoroethyl)-5-formamidopyrazole；[1-(2-fluoroethyl)-1H-pyrazol-5-yl]formamide；N-[2-(2-fluoroethyl)pyrazol-3-yl]formamide
• CAS: 144991-30-0
• 化学式: C₆H₈FN₃O
• 分子量: 157.147
• InChiKey: VYVWVHPJMWPMBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [1-(2-fluoroethyl)-1H-pyrazol-5-yl] formamide 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 3.5h， 生成 1-(2-fluoroethyl)-1H-pyrazol-5-amine
  参考文献：
  名称：

  [EN] CEPHEM COMPOUNDS
  [FR] COMPOSES CEPHEME

  摘要：

  本发明涉及一种具有以下式[I]的化合物：其中R1是较低的烷基、羟基(较低)烷基或卤代(较低)烷基，R2是氢或氨基保护基，或者R1和R2结合在一起形成较低的烷基或较低的烯基；R3是氢或较低的烷基；R4是；R5是羧基或保护羧基；R6是氨基或保护氨基，或其药学上可接受的盐，一种制备上述式[I]化合物的方法，以及包含上述式[I]化合物与药学上可接受的载体混合物的药物组合物。

  公开号：

  WO2004039814A1
• 作为产物：
  描述：

  5-氨基-1-(2-羟乙基)吡唑 在 N,N-二乙基-1,1,2,3,3,3-六氟丙胺 、 乙酸酐 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 [1-(2-fluoroethyl)-1H-pyrazol-5-yl] formamide
  参考文献：
  名称：

  Studies on 3′-quaternary ammonium cephalosporins—IV. Synthesis and antibacterial activity of 3′-(2-alkyl-3-aminopyrazolium)cephalosporins related to FK037

  摘要：

  The synthesis and in vitro antibacterial activity of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido] cephalosporins bearing various 2-alkyl-3-aminopyrazolium groups at the 3-position are described. Antibacterial activity against MRSA was affected by the nature of the substituent at the 2-position on the 3'-aminopyrazolium groups. Among the cephalosporins prepared in this study, 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[3-amino-2-(2-hydroxyethyl)-pyrazolio]methyl-3-cephem-4-carboxylate sulfate (23e, FK037) showed extremely potent broad-spectrum activity against both Gram-positive bacteria including MRSA, and Gram-negative bacteria including Pseudomonas aeruginosa. In particular, the in vivo activity against MRSA of FK037 was the highest of all the beta-lactam antibiotics tested. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00092-8

文献信息

• Cephem compounds
  申请人：Fujisawa Pharmaceutical Co., Ltd

  公开号：US20040132994A1

  公开（公告）日：2004-07-08

  The present invention relates to a compound of the formula [I]: 1 wherein R 1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R 2 is hydrogen or amino protecting group, or R 1 and R 2 are bonded together and form lower alkylene or lower alkenylene; R 3 is hydrogen or lower alkyl; R 4 is 2 R 5 is carboxy or protected carboxy; and R 6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种化合物，其分子式为[I]：1其中R1是低级烷基，羟基（低级）烷基或卤代（低级）烷基，而R2是氢或氨基保护基，或R1和R2相互结合形成低级亚烷基或低级烯基亚烷基；R3是氢或低级烷基；R4是2；R5是羧基或保护羧基；而R6是氨基或保护氨基，或其药学上可接受的盐，一种制备分子式[I]化合物的方法，以及包含分子式[I]化合物与药学上可接受的载体混合的制药组合物。
• CEPHEM COMPOUNDS
  申请人：Astellas Pharma Inc.

  公开号：EP1556389A1

  公开（公告）日：2005-07-27
• US7129232B2
  申请人：——

  公开号：US7129232B2

  公开（公告）日：2006-10-31
• [EN] CEPHEM COMPOUNDS<br/>[FR] COMPOSES CEPHEME
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004039814A1

  公开（公告）日：2004-05-13

  The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene or lower alkenylene; R3 is hydrogen or lower alkyl; R4 is ; R5 is carboxy or protected carboxy; and R6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种具有以下式[I]的化合物：其中R1是较低的烷基、羟基(较低)烷基或卤代(较低)烷基，R2是氢或氨基保护基，或者R1和R2结合在一起形成较低的烷基或较低的烯基；R3是氢或较低的烷基；R4是；R5是羧基或保护羧基；R6是氨基或保护氨基，或其药学上可接受的盐，一种制备上述式[I]化合物的方法，以及包含上述式[I]化合物与药学上可接受的载体混合物的药物组合物。
• Studies on 3′-quaternary ammonium cephalosporins—IV. Synthesis and antibacterial activity of 3′-(2-alkyl-3-aminopyrazolium)cephalosporins related to FK037
  作者：Hidenori Ohki、Kohji Kawabata、Yoshiko Inamoto、Shinya Okuda、Toshiaki Kamimura、Kazuo Sakane

  DOI：10.1016/s0968-0896(97)00092-8

  日期：1997.8

  The synthesis and in vitro antibacterial activity of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido] cephalosporins bearing various 2-alkyl-3-aminopyrazolium groups at the 3-position are described. Antibacterial activity against MRSA was affected by the nature of the substituent at the 2-position on the 3'-aminopyrazolium groups. Among the cephalosporins prepared in this study, 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[3-amino-2-(2-hydroxyethyl)-pyrazolio]methyl-3-cephem-4-carboxylate sulfate (23e, FK037) showed extremely potent broad-spectrum activity against both Gram-positive bacteria including MRSA, and Gram-negative bacteria including Pseudomonas aeruginosa. In particular, the in vivo activity against MRSA of FK037 was the highest of all the beta-lactam antibiotics tested. (C) 1997 Elsevier Science Ltd.